The LSTA last week submitted a comment letter to the European Banking Authority (EBA), arguing the case for why CLOs should be considered as eligible securitizations for the purpose of its ...

Lisata Therapeutics, Inc.’s LSTA lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treating a range of solid tumors. Earlier this month, the company ...

The Loan Syndications and Trading Association has met with key regulators regarding a lawsuit against major banks that aims to have term loans syndicated to institutional investors treated as ...

KBRA releases a recap of the annual CLO Conference hosted by the Loan Syndications & Trading Association (LSTA) and DealCatalyst, which took place at the Marriott Marquis Hotel in New York on April 27 ...

Our Distressed Debt & Claims Trading Team provides a summary of the changes the Loan Syndications and Trading Association made to their standard document in the wake of recent bankruptcies and circuit ...

The average one-year price target for Lisata Therapeutics (NasdaqCM:LSTA) has been revised to $11.56 / share. This is an increase of 19.30% from the prior estimate of $9.69 dated February 1, 2026. The ...

Haystack Oncology, a Quest Diagnostics Inc. (NYSE:DGX) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:LSTA). Haystack Oncology developed Haystack MRD, a ...

NEW YORK--(BUSINESS WIRE)--The Loan Syndications and Trading Association (LSTA) today announced a new partnership with DealCatalyst, bringing together the loan market leadership of the LSTA with the ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

NEW YORK--(BUSINESS WIRE)--The LSTA, the trade association for the corporate loan market, today released an essential Glossary of Private Corporate Credit (“PCC”) terms and an accompanying Frequently ...